A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate

Imatinib mesylate (IM) is used to treat a wide range of diseases, including Philadelphia chromosome-positive chronic myeloid leukemia (CML), on account of its high tolerability and low incidence of minor adverse events. Hemorrhage is thought to be a rare complication of IM. Recently, IM has been ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Min Sik, Lee, Dong Hyun, Lee, Yu Rim, Kim, Dong Kyun, Bae, Suk Hyang, Hwang, Jin Yeon, Kwon, Kyung A, Lee, Suee, Han, Jin Yeong, Kim, Ki Uk, Kim, Sung-Hyun
Formato: Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2983009/
https://www.ncbi.nlm.nih.gov/pubmed/21120168
http://dx.doi.org/10.5045/kjh.2010.45.1.73
Descripción
Sumario:Imatinib mesylate (IM) is used to treat a wide range of diseases, including Philadelphia chromosome-positive chronic myeloid leukemia (CML), on account of its high tolerability and low incidence of minor adverse events. Hemorrhage is thought to be a rare complication of IM. Recently, IM has been associated with reduced α2-plasmin inhibitor and platelet dysfunction. We report here the case of a 33-year-old female patient with CML who experienced subdural hematoma after an incremental increase in IM dosage due to a loss of complete molecular response. This case indicates that physicians should be alert to this atypical cause of headache in patients taking high-dose IM.

Ejemplares similares